Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

MAP to Provide Access to Crizanlizumab, for Sickle Cell Disease Patients

Conditions: Sickle Cell Disease

First Posted Date: 2018-10-25

Last Posted Date: 2024-10-28

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT03720626

Study of Efficacy and Safety of Eltrombopag in Patients With Poor Graft Function

Phase 2

Terminated

Conditions: Poor Graft Function

Interventions: Drug: Eltrombopag

First Posted Date: 2018-10-24

Last Posted Date: 2024-02-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 10

Registration Number: NCT03718533

Locations: 🇪🇸
Novartis Investigative Site, Barcelona, Spain

This is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).

Phase 3

Completed

Conditions: Hidradenitis Suppurativa

Interventions: Drug: Placebo
Drug: secukinumab

First Posted Date: 2018-10-22

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 545

Registration Number: NCT03713619

Locations: 🇬🇧
Novartis Investigative Site, Norwich, United Kingdom

Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)

Phase 3

Completed

Conditions: Hidradenitis Suppurativa

Interventions: Drug: Secukinumab
Drug: Placebo

First Posted Date: 2018-10-22

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 545

Registration Number: NCT03713632

Locations: 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam

Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections

Phase 3

Terminated

Conditions: Age-Related Macular Degeneration

Interventions: Biological: Aflibercept
Biological: Brolucizumab

First Posted Date: 2018-10-18

Last Posted Date: 2023-01-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 535

Registration Number: NCT03710564

Locations: 🇵🇷
Novartis Investigative Site, Arecibo, Puerto Rico

Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer

Conditions: HR+ Advanced or Metastatic Breast Cancer

First Posted Date: 2018-10-16

Last Posted Date: 2021-07-19

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT03706573

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

Phase 3

Active, not recruiting

Conditions: Early Breast Cancer

Interventions: Other: Endocrine Therapy
Drug: Ribociclib

First Posted Date: 2018-10-10

Last Posted Date: 2024-11-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 5101

Registration Number: NCT03701334

Locations: 🇺🇸
University of Alabama at Birmingham-Kirklin Clinic, Birmingham, Alabama, United States
🇺🇸
Cancer Treatment Centers of America, Zion, Illinois, United States
🇺🇸
Comprehensive Blood and Cancer, Bakersfield, California, United States

and more 69 locations

Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer

Phase 1

Completed

Conditions: NON-breast HER2+ Malignancies

Interventions: Drug: NJH395

First Posted Date: 2018-10-05

Last Posted Date: 2022-02-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 18

Registration Number: NCT03696771

Locations: 🇰🇷
Novartis Investigative Site, Seoul, Korea, Republic of
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects

Phase 1

Completed

Conditions: Non-alcoholic Fatty Liver Disease

Interventions: Drug: LJN452

First Posted Date: 2018-09-24

Last Posted Date: 2020-12-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 42

Registration Number: NCT03681457

Locations: 🇺🇸
Novartis Investigative Site, Knoxville, Tennessee, United States

Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma

Phase 3

Completed

Conditions: Nasal Polyps

Interventions: Drug: Fevipiprant 150 mg
Drug: Fevipiprant 450 mg
Drug: Placebo

First Posted Date: 2018-09-21

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 98

Registration Number: NCT03681093

Locations: 🇵🇱
Novartis Investigative Site, Zawadzkie, Poland

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy